<p>首个可穿戴肽贴片旨在将 BPC-157 从注射剂扩展到多产品经皮肽平台，隶属于 Amino Innovations</p>
<p>加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 7 日）-- <strong>精准肽公司 (CSE: BPC) (OTCQB: PNGAF) (以下简称 “公司” 或 “BPC”)</strong>，一家专注于先进肽配方和输送系统的上市健康公司，今天提供了关于其无针 BPC-157 经皮贴片开发的最新进展——这一产品旨在为消费者首次提供无摩擦的肽类产品进入途径。</p>
<p>BPC-157 贴片目前正在积极测试中，预计近期将有结果。若这些测试里程碑顺利完成，公司计划将该产品推进至商业发布阶段，作为精准肽公司产品组合的一部分。</p>
<p>数十年来，肽类产品一直受到针头的限制。尽管在恢复、长寿和更广泛的健康领域对肽的兴趣迅速增长，但大多数消费者从未跨越进入这一领域的门槛——研究一致表明，针头恐惧是消费者本可以考虑的疗法的主要障碍。因此，采用者主要集中在已经习惯自我注射的生物黑客、运动员和临床人群中。</p>
<p>这一创新贴片旨在完全消除这一障碍。直接贴在皮肤上，经过精确设计以实现控制和持续的肽输送，该贴片消除了与注射肽疗法相关的重组、无菌处理和剂量测量。最终结果是一个可穿戴的、适合主流市场的格式，旨在将 BPC-157 和其他配方带给那些远观肽类产品并一直在等待他们实际会使用的输送格式的消费者。</p>
<p>精准肽公司的首席执行官 Pratap Sandhu 评论道：</p>
<p>“这是将肽带入主流的产品。针头历来是这一领域最大的进入障碍，去除它从根本上改变了客户的面貌。该贴片是为那些阅读过头条新闻、听过播客并决定肽不适合他们的人设计的，因为他们不愿意注射。我们相信它是肽类产品的起源与更大消费者市场之间的桥梁，而迄今为止的测试进展支持了我们对这一路径的信心。”</p>
<p>Amino Innovations 的首席科学官 Justin Kirkland 补充道：</p>
<p>“BPC-157 背后有数十年的临床前研究，将该分子从注射剂转化为经皮格式是一项重要的配方工作。该贴片经过设计，能够以可靠的方式通过皮肤持续输送，表现出在非注射环境下的可靠性。我们通过这一测试项目生成的数据使我们对该贴片作为传统肽给药的可信、可扩展替代品充满信心——在我们看来，这是该类别如何接触日常消费者的一大进步。”</p>
<p>BPC-157 贴片是公司更广泛的经皮贴片管道中首个推进的产品。第二个贴片——公司的免疫防御贴片，采用胸腺素 Alpha-1 (TA-1) 配方，并在相同的输送平台上开发，也在开发中，预计将在测试后跟随 BPC-157 走向商业准备。两个产品共同旨在建立一个无针肽类产品的多产品平台，隶属于 Amino Innovations 品牌。</p>
<p>贴片开发得到了公司之前与阿尔伯塔大学药物开发与创新中心 (DDIC) 签署的研究服务协议的支持，Neal Davies 博士和 Raimar Loebenberg 博士是药学与药物科学学院的高级教授，提供与公司肽产品组合相关的吸收、生物利用度和稳定性方面的科学专业知识。</p>
<p>BPC-157 贴片将与公司现有的口服肽产品线并列，该产品线在美国获得批准的设施中生产，并通过 Amino Innovations 品牌在北美分销。</p>
<p>目前正在进行的测试无法保证会产生满足公司内部基准的结果，BPC-157 贴片或免疫防御贴片是否会在当前预期的时间表上商业化，或任何后续产品发布是否会为公司带来收入或其他利益。公司将在发生重大进展时提供进一步更新。</p>
<p><strong>关于精准肽公司</strong></p>
<p>精准肽公司 (CSE: BPC) (OTCQB: PNGAF) 是一家上市健康公司，正在建立一个高质量肽配方的下一代平台。通过结合科学配方和创新输送技术，公司创造出位于生物技术与可扩展消费者健康交汇处的产品。产品在美国获得批准的设施中生产，并在北美分销。</p>
<p>欲了解更多信息，请访问：www.precisionpeptidecompany.com</p>
<p><strong>关于前瞻性信息的警示说明</strong></p>
<p><strong>本新闻稿包含适用的加拿大证券法意义上的 “前瞻性信息”。前瞻性信息包括但不限于与以下内容相关的声明：对 BPC-157 透皮贴片测试的预期时间和结果；公司推进 BPC-157 贴片商业发布的意图；免疫防御贴片的预期开发和商业化；在 Amino Innovations 品牌下建立多产品无针肽平台；以及公司与阿尔伯塔大学药物开发与创新中心（DDIC）研究服务协议的预期收益。</strong></p>
<p><strong>前瞻性信息基于公司做出的某些关键期望和假设，包括：BPC-157 贴片的测试将按照当前设想的时间表进行，并产生与公司内部基准一致的结果；没有不利的监管、科学、制造或供应链发展会实质性延迟或阻止公司产品的商业化；与 DDIC 的研究服务协议将继续保持当前形式；以及一般商业和经济条件不会以对公司不利的方式发生变化。</strong></p>
<p><strong>尽管公司相信前瞻性信息所基于的期望和假设是合理的，但不应对前瞻性信息过度依赖，因为公司无法保证这些信息将被证明是正确的。由于前瞻性信息涉及未来事件和条件，其本质上涉及固有的风险和不确定性。实际结果可能因多种因素和风险而与当前预期大相径庭，包括但不限于：BPC-157 贴片测试未能产生令人满意的结果的风险；公司无法在当前设想的时间表内，或根本无法商业化 BPC-157 贴片或免疫防御贴片的风险；BPC-157 的透皮给药未能实现足够的生物利用度或消费者接受度的风险；以及任何后续产品发布未能为公司带来收入或其他收益的风险。</strong></p>
<p><strong>本新闻稿中包含的前瞻性信息截至本日期发布，公司没有义务公开更新或修订任何前瞻性信息，无论是由于新信息、未来事件还是其他原因，除非适用的证券法要求。</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/296392</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375"/></p>

PRAX

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

<p>精准肽公司即将商业推出其无针 BPC-157 透皮贴片，旨在通过消除注射的需要，使肽疗法更易于获取。目前该贴片正在积极测试中，旨在实现肽的控制释放，并瞄准更广泛的消费者市场。公司还计划开发其他贴片，包括免疫防御贴片。首席执行官 Pratap Sandhu 强调，这一创新可能会显著改变消费者与肽疗法的互动。公司正在与阿尔伯塔大学合作，为贴片的开发提供科学支持</p>

<p>First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations</p>
<div class="lb-trans"><p>首个可穿戴肽贴片旨在将 BPC-157 从注射剂扩展到多产品经皮肽平台，隶属于 Amino Innovations</p>
</div><p>Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - <strong>The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the &#34;Company&#34; or &#34;BPC&#34;)</strong>, a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time.</p>
<div class="lb-trans"><p>加拿大不列颠哥伦比亚省温哥华 --（Newsfile Corp. -2026 年 5 月 7 日）-- <strong>精准肽公司 (CSE: BPC) (OTCQB: PNGAF) (以下简称 “公司” 或 “BPC”)</strong>，一家专注于先进肽配方和输送系统的上市健康公司，今天提供了关于其无针 BPC-157 经皮贴片开发的最新进展——这一产品旨在为消费者首次提供无摩擦的肽类产品进入途径。</p>
</div><p>The BPC-157 patch is currently in active testing, with results anticipated in the near term. Subject to the satisfactory completion of these testing milestones, the Company intends to progress the product closer to commercial release as part of The Precision Peptide Company's product portfolio.</p>
<div class="lb-trans"><p>BPC-157 贴片目前正在积极测试中，预计近期将有结果。若这些测试里程碑顺利完成，公司计划将该产品推进至商业发布阶段，作为精准肽公司产品组合的一部分。</p>
</div><p>For decades, the peptide category has been gated by the needle. While interest in peptides has grown rapidly across recovery, longevity, and broader wellness, the majority of consumers have never crossed the threshold into the category - research consistently identifies needle aversion as a leading barrier to therapies that consumers would otherwise consider. Adoption has therefore skewed toward biohackers, athletes, and clinical populations already comfortable with self-administered injectables.</p>
<div class="lb-trans"><p>数十年来，肽类产品一直受到针头的限制。尽管在恢复、长寿和更广泛的健康领域对肽的兴趣迅速增长，但大多数消费者从未跨越进入这一领域的门槛——研究一致表明，针头恐惧是消费者本可以考虑的疗法的主要障碍。因此，采用者主要集中在已经习惯自我注射的生物黑客、运动员和临床人群中。</p>
</div><p>The innovative patch is designed to remove that barrier entirely. Worn directly on the skin and precision-engineered for controlled, sustained peptide delivery, the patch eliminates the reconstitution, sterile handling, and dose measurement associated with injectable peptide therapies. The result is a wearable, mainstream-ready format intended to bring BPC-157 and other formulas to consumers who have followed the rise of peptides from a distance and have been waiting for a delivery format they would actually use.</p>
<div class="lb-trans"><p>这一创新贴片旨在完全消除这一障碍。直接贴在皮肤上，经过精确设计以实现控制和持续的肽输送，该贴片消除了与注射肽疗法相关的重组、无菌处理和剂量测量。最终结果是一个可穿戴的、适合主流市场的格式，旨在将 BPC-157 和其他配方带给那些远观肽类产品并一直在等待他们实际会使用的输送格式的消费者。</p>
</div><p>Pratap Sandhu, CEO of The Precision Peptide Company, commented:</p>
<div class="lb-trans"><p>精准肽公司的首席执行官 Pratap Sandhu 评论道：</p>
</div><p>&#34;This is the product that brings peptides into the mainstream. The needle has historically been the single biggest barrier to entry for this category, and removing it fundamentally changes who the customer is. The patch is built for the person who has read the headlines, listened to the podcasts, and decided peptides aren't for them because they aren't willing to inject. We believe it is the bridge between where peptides have come from and the far larger consumer market they can serve, and the progression of testing to date supports our confidence in that path.&#34;</p>
<div class="lb-trans"><p>“这是将肽带入主流的产品。针头历来是这一领域最大的进入障碍，去除它从根本上改变了客户的面貌。该贴片是为那些阅读过头条新闻、听过播客并决定肽不适合他们的人设计的，因为他们不愿意注射。我们相信它是肽类产品的起源与更大消费者市场之间的桥梁，而迄今为止的测试进展支持了我们对这一路径的信心。”</p>
</div><p>Justin Kirkland, Chief Scientific Officer of Amino Innovations, added:</p>
<div class="lb-trans"><p>Amino Innovations 的首席科学官 Justin Kirkland 补充道：</p>
</div><p>&#34;BPC-157 has decades of preclinical research behind it, and translating that molecule from an injectable into a transdermal format is a meaningful piece of formulation work. The patch is engineered to deliver consistently through the skin in a way that performs reliably outside of an injection setting. The data we are generating through this testing programme is what gives us confidence in the patch as a credible, scalable alternative to traditional peptide administration - and, in our view, a real step forward for how the category reaches everyday consumers.&#34;</p>
<div class="lb-trans"><p>“BPC-157 背后有数十年的临床前研究，将该分子从注射剂转化为经皮格式是一项重要的配方工作。该贴片经过设计，能够以可靠的方式通过皮肤持续输送，表现出在非注射环境下的可靠性。我们通过这一测试项目生成的数据使我们对该贴片作为传统肽给药的可信、可扩展替代品充满信心——在我们看来，这是该类别如何接触日常消费者的一大进步。”</p>
</div><p>The BPC-157 patch is the first product to advance from the Company's broader transdermal patch pipeline. A second patch - the Company's Immune Defense Patch, formulated with Thymosin Alpha-1 (TA-1) and developed on the same delivery platform - is also under development, and is expected to follow BPC-157 through testing and toward commercial readiness in due course. Together, the two products are intended to establish the foundation of a multi-product needle-free peptide platform under the Amino Innovations brand.</p>
<div class="lb-trans"><p>BPC-157 贴片是公司更广泛的经皮贴片管道中首个推进的产品。第二个贴片——公司的免疫防御贴片，采用胸腺素 Alpha-1 (TA-1) 配方，并在相同的输送平台上开发，也在开发中，预计将在测试后跟随 BPC-157 走向商业准备。两个产品共同旨在建立一个无针肽类产品的多产品平台，隶属于 Amino Innovations 品牌。</p>
</div><p>Patch development is supported by the Company's previously announced research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta, where Dr. Neal Davies and Dr. Raimar Loebenberg, senior professors in the Faculty of Pharmacy and Pharmaceutical Sciences, provide scientific expertise across absorption, bioavailability, and stability work relevant to the Company's peptide portfolio.</p>
<div class="lb-trans"><p>贴片开发得到了公司之前与阿尔伯塔大学药物开发与创新中心 (DDIC) 签署的研究服务协议的支持，Neal Davies 博士和 Raimar Loebenberg 博士是药学与药物科学学院的高级教授，提供与公司肽产品组合相关的吸收、生物利用度和稳定性方面的科学专业知识。</p>
</div><p>The BPC-157 patch will sit alongside the Company's existing oral peptide product line, manufactured in an approved U.S. facility and distributed across North America through the Amino Innovations brand.</p>
<div class="lb-trans"><p>BPC-157 贴片将与公司现有的口服肽产品线并列，该产品线在美国获得批准的设施中生产，并通过 Amino Innovations 品牌在北美分销。</p>
</div><p>There is no assurance that the testing currently underway will produce results that satisfy the Company's internal benchmarks, that the BPC-157 patch or the Immune Defense Patch will be commercialised on the timelines currently contemplated, or that any subsequent product launch will result in revenue or other benefit to the Company. The Company will provide further updates as material developments occur.</p>
<div class="lb-trans"><p>目前正在进行的测试无法保证会产生满足公司内部基准的结果，BPC-157 贴片或免疫防御贴片是否会在当前预期的时间表上商业化，或任何后续产品发布是否会为公司带来收入或其他利益。公司将在发生重大进展时提供进一步更新。</p>
</div><p><strong>About The Precision Peptide Company</strong></p>
<div class="lb-trans"><p><strong>关于精准肽公司</strong></p>
</div><p>The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.</p>
<div class="lb-trans"><p>精准肽公司 (CSE: BPC) (OTCQB: PNGAF) 是一家上市健康公司，正在建立一个高质量肽配方的下一代平台。通过结合科学配方和创新输送技术，公司创造出位于生物技术与可扩展消费者健康交汇处的产品。产品在美国获得批准的设施中生产，并在北美分销。</p>
</div><p>For more information, visit: www.precisionpeptidecompany.com</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：www.precisionpeptidecompany.com</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示说明</strong></p>
</div><p><strong>This news release contains &#34;forward-looking information&#34; within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements relating to: the anticipated timing and outcome of testing of the BPC-157 transdermal patch; the Company's intention to progress the BPC-157 patch toward commercial release; the anticipated development and commercialization of the Immune Defense Patch; the establishment of a multi-product needle-free peptide platform under the Amino Innovations brand; and the expected benefits of the Company's research services agreement with the Drug Development and Innovation Centre (DDIC) at the University of Alberta.</strong></p>
<div class="lb-trans"><p><strong>本新闻稿包含适用的加拿大证券法意义上的 “前瞻性信息”。前瞻性信息包括但不限于与以下内容相关的声明：对 BPC-157 透皮贴片测试的预期时间和结果；公司推进 BPC-157 贴片商业发布的意图；免疫防御贴片的预期开发和商业化；在 Amino Innovations 品牌下建立多产品无针肽平台；以及公司与阿尔伯塔大学药物开发与创新中心（DDIC）研究服务协议的预期收益。</strong></p>
</div><p><strong>Forward-looking information is based on certain key expectations and assumptions made by the Company, including that: testing of the BPC-157 patch will proceed on the timelines currently contemplated and will produce results consistent with the Company's internal benchmarks; no adverse regulatory, scientific, manufacturing, or supply chain developments will materially delay or prevent commercialization of the Company's products; the research services agreement with the DDIC will continue in its current form; and general business and economic conditions will not change in a manner materially adverse to the Company.</strong></p>
<div class="lb-trans"><p><strong>前瞻性信息基于公司做出的某些关键期望和假设，包括：BPC-157 贴片的测试将按照当前设想的时间表进行，并产生与公司内部基准一致的结果；没有不利的监管、科学、制造或供应链发展会实质性延迟或阻止公司产品的商业化；与 DDIC 的研究服务协议将继续保持当前形式；以及一般商业和经济条件不会以对公司不利的方式发生变化。</strong></p>
</div><p><strong>Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, but not limited to: the risk that testing of the BPC-157 patch does not produce satisfactory results; the risk that the Company is unable to commercialize the BPC-157 patch or the Immune Defense Patch on the timelines currently contemplated, or at all; the risk that the transdermal delivery of BPC-157 does not achieve adequate bioavailability or consumer acceptance; and the risk that any subsequent product launch does not result in revenue or other benefit to the Company.</strong></p>
<div class="lb-trans"><p><strong>尽管公司相信前瞻性信息所基于的期望和假设是合理的，但不应对前瞻性信息过度依赖，因为公司无法保证这些信息将被证明是正确的。由于前瞻性信息涉及未来事件和条件，其本质上涉及固有的风险和不确定性。实际结果可能因多种因素和风险而与当前预期大相径庭，包括但不限于：BPC-157 贴片测试未能产生令人满意的结果的风险；公司无法在当前设想的时间表内，或根本无法商业化 BPC-157 贴片或免疫防御贴片的风险；BPC-157 的透皮给药未能实现足够的生物利用度或消费者接受度的风险；以及任何后续产品发布未能为公司带来收入或其他收益的风险。</strong></p>
</div><p><strong>The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.</strong></p>
<div class="lb-trans"><p><strong>本新闻稿中包含的前瞻性信息截至本日期发布，公司没有义务公开更新或修订任何前瞻性信息，无论是由于新信息、未来事件还是其他原因，除非适用的证券法要求。</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8944/296392_c538c1950414bba7_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296392</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/296392</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296392/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/296392/375"/></p>

The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances | PNGAF Stock News

StockTitan

Praxis Precision Medicines

标普生物技术 3 倍做多 - Direxion

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

精密肽公司在无针 BPC-157 贴片的商业发布上取得进展，最终测试正在推进 | PNGAF 股票新闻